Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539874 | 1.00 | MAPT (0.41) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL2689048 | 0.92 | IP6K1 (0.39) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL2689049 | 0.92 | IP6K1 (0.39) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL15554506 | 0.90 | NFE2L2 (0.39) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL15555761 | 0.90 | MAPT (0.38) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL15555762 | 0.90 | MAPT (0.38) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL15554877 | 0.89 | ALDH1A1 (0.37) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL15554262 | 0.86 | CCNC (0.37) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL15555463 | 0.85 | CCNC (0.47) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL28224850 | 0.84 | ALDH1A1 (0.44) | MAPTALDH1A1KDM4EKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1568695-B1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | KOREA INST SCI & TECH (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-7271260-B2 | 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-09-18 | — | — | US | disclosed |
| US-20050197351-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2005-09-08 | — | — | US | disclosed |
| EP-1568695-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | Korea Institute of Science and Technology (KR) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197351-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | CACNA1I, CACNA1G, CACNA1H | MAPT 429/4885ALDH1A1 3052/4885KDM4E 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.